Volume 97, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Artemisinin-based combination therapies are the frontline treatment of malaria. The circulation of falsified and substandard artemisinin-based antimalarials in Southeast Asia has been a major predicament for the malaria elimination campaign. To provide an update of this situation, we purchased 153 artemisinin-containing antimalarials, as convenience samples, in private drug stores from different regions of Myanmar. The quality of these drugs in terms of their artemisinin derivative content was tested using specific dipsticks for these artemisinin derivatives, as point-of-care devices. A subset of these samples was further tested by high-performance liquid chromatography (HPLC). This survey identified that > 35% of the collected drugs were oral artesunate and artemether monotherapies. When tested with the dipsticks, all but one sample passed the assays, indicating that the detected artemisinin derivative content corresponded approximately to the labeled contents. However, one artesunate injection sample was found to contain no active ingredient at all by the dipstick assay and subsequent HPLC analysis. The continued circulation of oral monotherapies and the description, for the first time, of falsified parenteral artesunate provides a worrisome picture of the antimalarial drug quality in Myanmar during the malaria elimination phase, a situation that deserves more oversight from regulatory authorities.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Nayyar GM, Breman JG, Newton PN, Herrington J, , 2012. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 12: 488496.[Crossref] [Google Scholar]
  2. Newton PN, ., 2006. Manslaughter by fake artesunate in Asia–will Africa be next? PLoS Med 3: e197.[Crossref] [Google Scholar]
  3. Newton PN, Caillet C, Guerin PJ, , 2016. A link between poor quality antimalarials and malaria drug resistance? Expert Rev Anti Infect Ther 14: 531533.[Crossref] [Google Scholar]
  4. Newton PN, ., 2008. A collaborative epidemiological investigation into the criminal fake artesunate trade in southeast Asia. PLoS Med 5: e32.[Crossref] [Google Scholar]
  5. Dondorp AM, ., 2004. Fake antimalarials in southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 9: 12411246.[Crossref] [Google Scholar]
  6. Newton P, ., 2001. Fake artesunate in southeast Asia. Lancet 357: 19481950.[Crossref] [Google Scholar]
  7. Sengaloundeth S, ., 2009. A stratified random survey of the proportion of poor quality oral artesunate sold at medicine outlets in the Lao PDR – implications for therapeutic failure and drug resistance. Malar J 8: 172.[Crossref] [Google Scholar]
  8. Phanalasy S, , 2017. The malaria testing and treatment landscape in the southern Lao People’s Democratic Republic (PDR). Malar J 16: 169.[Crossref] [Google Scholar]
  9. Tabernero P, ., 2015. A repeat random survey of the prevalence of falsified and substandard antimalarials in the Lao PDR: a change for the better. Am J Trop Med Hyg 92: 95104.[Crossref] [Google Scholar]
  10. Khin HS, Aung T, Aung M, Thi A, Boxshall M, White C, , 2016. Using supply side evidence to inform oral artemisinin monotherapy replacement in Myanmar: a case study. Malar J 15: 418.[Crossref] [Google Scholar]
  11. Khin HS, Aung T, Thi A, White C, , 2016. Oral artemisinin monotherapy removal from the private sector in eastern Myanmar between 2012 and 2014. Malar J 15: 286.[Crossref] [Google Scholar]
  12. Thein ST, Khin HSS, Thi A, , 2017. Anti-malarial landscape in Myanmar: results from a nationally representative survey among community health workers and the private sector outlets in 2015/2016. Malar J 16: 129.[Crossref] [Google Scholar]
  13. Thein ST, Khin HSS, Thi A, , 2017. Insights into the availability and distribution of oral artemisinin monotherapy in Myanmar: evidence from a nationally representative outlet survey. Malar J 16: 170.[Crossref] [Google Scholar]
  14. WHO, 2007. World Health Assembly Resolution WHA60.18. Available at: http://www.who.int/tdr/about/governance/documents/WHA60.18.pdf. Accessed July 16, 2017.
  15. Fairhurst RM, Dondorp AM, , 2016. Artemisinin-resistant Plasmodium falciparum malaria. Microbiol Spectr 4: EI10-0013-2016. [Google Scholar]
  16. Cui L, ., 2012. Malaria in the greater Mekong subregion: heterogeneity and complexity. Acta Trop 121: 227239.[Crossref] [Google Scholar]
  17. Hewitt S, Delacollette C, Poirot E, , 2013. Malaria control in the greater Mekong subregion: an overview of the current response and its limitations. Southeast Asian J Trop Med Public Health 44 ( Suppl 1 ): 249305, discussion 306–307. [Google Scholar]
  18. Guo S, Cui Y, He L, Zhang L, Cao Z, Zhang W, Zhang R, Tan G, Wang B, Cui L, , 2013. Development of a specific monoclonal antibody-based ELISA to measure the artemether content of antimalarial drugs. PLoS One 8: e79154.[Crossref] [Google Scholar]
  19. He L, Nan T, Cui Y, Guo S, Zhang W, Zhang R, Tan G, Wang B, Cui L, , 2014. Development of a colloidal gold-based lateral flow dipstick immunoassay for rapid qualitative and semi-quantitative analysis of artesunate and dihydroartemisinin. Malar J 13: 127.[Crossref] [Google Scholar]
  20. Guo S, Cui Y, Wang K, Zhang W, Tan G, Wang B, Cui L, , 2016. Development of a specific monoclonal antibody for the quantification of artemisinin in Artemisia annua and rat serum. Anal Chem 88: 27012706.[Crossref] [Google Scholar]
  21. Guo S, He L, Tisch DJ, Kazura J, Mharakurwa S, Mahanta J, Herrera S, Wang B, Cui L, , 2016. Pilot testing of dipsticks as point-of-care assays for rapid diagnosis of poor-quality artemisinin drugs in endemic settings. Trop Med Health 44: 15.[Crossref] [Google Scholar]
  22. Guo S, Zhang W, He L, Tan G, Min M, Kyaw MP, Wang B, Cui L, , 2016. Rapid evaluation of artesunate quality with a specific monoclonal antibody-based lateral flow dipstick. Anal Bioanal Chem 408: 60036008.[Crossref] [Google Scholar]
  23. Newton PN, ., 2009. Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med 6: e52.[Crossref] [Google Scholar]
  24. Guo S, Zhang W, He L, Tan G, Min M, Kyaw MP, Wang B, Cui L, , 2016. Rapid evaluation of artesunate quality with a specific monoclonal antibody-based lateral flow dipstick. Anal Bioanal Chem 408: 60036008.[Crossref] [Google Scholar]
  25. Batty KT, Davis TM, Thu LT, Binh TQ, Anh TK, Ilett KF, , 1996. Selective high-performance liquid chromatographic determination of artesunate and alpha- and beta-dihydroartemisinin in patients with falciparum malaria. J Chromatogr B Biomed Appl 677: 345350.[Crossref] [Google Scholar]
  26. Karbwang J, Na-Bangchang K, Molunto P, Banmairuroi V, Congpuong K, , 1997. Determination of artemether and its major metabolite, dihydroartemisinin, in plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 690: 259265.[Crossref] [Google Scholar]
  27. Dondorp A, Nosten F, Stepniewska K, Day N, White N, , 2005. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366: 717725.[Crossref] [Google Scholar]
  28. Dondorp AM, ., 2010. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376: 16471657.[Crossref] [Google Scholar]
  29. WHO, 2015. Guidelines for the Treatment of Malaria. 3rd edition. Geneva, Switzerland: World Health Organization, 316.

Data & Media loading...

  • Received : 12 Apr 2017
  • Accepted : 15 Jun 2017
  • Published online : 31 Jul 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error